SDC1 and Miyoshi myopathy: The BCMA-BTZ-NPs showed remarkable efficacy not only in MM cell lines but also CD138+ primary MM cells from patients, where they enhanced MM cytotoxicity with minimal effect CD138- cells compared to free BTZ.